Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 1, 2010, Pages 65-70

  Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Goto, Naoe ^a   Kitagawa, Jun Ichi ^a   Kanemura, Nobuhiro ^a   Yoshikawa, Takeshi ^a   Kasahara, Senji ^a   Goto, Hideko ^b   Fukuno, Kenji ^c   Yamada, Toshiki ^d   Sawada, Michio ^c   Yasuda, Ichiro ^a   Katsumura, Naoki ^a   Takahashi, Takeshi ^d   Takami, Tsuyoshi ^e   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kisogawa Municipal Hospital   (Japan)

^c Gifu Red Cross Hospital   (Japan)

^d Gifu Municipal Hospital   (Japan)

^e GIFU UNIVERSITY   (Japan)

Author keywords

Non Hodgkin's lymphoma; Pirarubicin; R CHOP; R THP COP

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; SEROTONIN 3 ANTAGONIST; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; LUNG TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PREDNISOLONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 71449091635     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0637-x     Document Type: Article

References (26)

1. A predictive model for aggressive non-Hodgkin's lymphoma 1993 The international non-Hodgkin's lymphoma prognostic factors project N Engl J Med 329 987 994 10.1056/NEJM199309303291402 (Pubitemid 23307906)
2. S Aoki N Tsukada N Nomoto S Maruyama M Takahashi Y Moriyama A Shibata Y Aizawa 1998 Effect of pirarubicin for elderly patients with malignant lymphoma J Exp Clin Cancer Res 17 465 470 1:STN:280:DyaK1M7os12gsg%3D%3D 10089069
3. M Bertini R Freilone U Vitolo B Botto M Pizzuti P Gavarotti A Levis E Orlandi L Orsucci M Pini, et al. 1994 P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL) Ann Oncol 5 895 900 1:STN:280:DyaK2M3htVWnsQ%3D%3D 7535080
4. M Bertini R Freilone U Vitolo B Botto R Ciotti S Cinieri A Di Nota F Di Vito A Levis L Orsucci M Pini D Rota-Scalabrini G Todeschini L Resegotti 1996 The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen Leuk Lymphoma 22 483 493 10.3109/10428199609054787 10.3109/10428199609054787 1:STN:280: DyaK2s%2Fjsleitw%3D%3D 8882962
5. PP Carbone HS Kaplan K Musshoff DW Smithers M Tubiana 1971 Report of the Committee on Hodgkin's Disease Staging Classification Cancer Res 31 1860 1861 1:STN:280:DyaE38%2Fks1yitw%3D%3D 5121694
6. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-Lopez A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D 10561185
7. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D 11807147 (Pubitemid 34438862)
8. DR Cox 1972 Regression models and life-tables (with discussions) J Roy Statist Soc Ser B Methodol 34 187 220
9. JK Doorduijn B van der Holt GW van Imhoff KG van der Hem MH Kramer MH van Oers GJ Ossenkoppele MR Schaafsma LF Verdonck GE Verhoef MM Steijaert I Buijt CA Uyl-de Groot M van Agthoven AH Mulder P Sonneveld 2003 CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma J Clin Oncol 21 3041 3050 10.1200/JCO.2003.01. 076 10.1200/JCO.2003.01.076 1:CAS:528:DC%2BD2cXpsVWqtL8%3D 12915593 (Pubitemid 46606283)
10. RI Fisher P Shah 2003 Current trends in large cell lymphoma Leukemia 17 1948 1960 10.1038/sj.leu.2403096 10.1038/sj.leu.2403096 1:CAS:528: DC%2BD3sXnsF2ms7k%3D 14513044 (Pubitemid 37322124)
11. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize JH Glick CA Coltman Jr TP Miller 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 10.1056/NEJM199304083281404 10.1056/NEJM199304083281404 1:STN:280:DyaK3s7ps1Kmtg%3D%3D 7680764 (Pubitemid 23095683)
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 109-236
13. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868 10.2307/2281868
14. K Kitamura F Takaku 1990 Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly Am J Clin Oncol 13 Suppl 1 S15 S19 10.1097/00000421-199012001-00005 2291455
15. AA Miller E Salewski 1994 Prospects for pirarubicin Med Pediatr Oncol 22 261 268 10.1002/mpo.2950220410 10.1002/mpo.2950220410 1:STN:280: DyaK2c7ltVCitw%3D%3D 8107658 (Pubitemid 2037590)
16. M Mori K Kitamura M Masuda T Hotta T Miyazaki AB Miura H Mizoguchi A Shibata H Saito T Matsuda T Masaoka M Harada Y Niho F Takaku 2005 Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma Int J Hematol 81 246 254 10.1532/IJH97.03147 10.1532/IJH97.03147 1:CAS:528:DC%2BD2MXkslGhur4%3D 15814336 (Pubitemid 41364491)
17. N Niitsu M Umeda 1997 THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study Leukemia 11 1817 1820 10.1038/sj.leu. 2400001 10.1038/sj.leu.2400001 1:CAS:528:DyaK1cXktF2ksr4%3D 9369412
18. M Pfreundschuh L Trumper M Kloess R Schmits AC Feller C Rube C Rudolph M Reiser DK Hossfeld H Eimermacher D Hasenclever N Schmitz M Loeffler 2004 Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 634 641 10.1182/blood-2003-06-2095 10.1182/blood-2003-06-2095 1:CAS:528:DC%2BD2cXmtlCkt7Y%3D 15016643 (Pubitemid 38970554)
19. M Pfreundschuh AD Ho E Cavallin-Stahl M Wolf R Pettengell I Vasova A Belch J Walewski PL Zinzani W Mingrone S Kvaloy O Shpilberg U Jaeger M Hansen C Corrado A Scheliga M Loeffler E Kuhnt 2008 Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Lancet Oncol 9 435 444 10.1016/S1470-2045(08)70078-0 10.1016/S1470-2045(08)70078-0 18400558
20. M Pfreundschuh J Schubert M Ziepert R Schmits M Mohren E Lengfelder M Reiser C Nickenig M Clemens N Peter C Bokemeyer H Eimermacher A Ho M Hoffmann R Mertelsmann L Trumper L Balleisen R Liersch B Metzner F Hartmann B Glass V Poeschel N Schmitz C Ruebe AC Feller M Loeffler 2008 Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105 116 10.1016/S1470-2045(08)70002-0 10.1016/S1470-2045(08)70002-0 1:CAS:528:DC%2BD1cXhsVOnu7g%3D 18226581
21. M Sawada H Tsurumi T Yamada T Hara K Fukuno H Goto M Shimizu S Kasahara T Yoshikawa N Kanemura M Oyama T Takami H Moriwaki 2002 A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy Eur J Haematol 68 354 361 10.1034/j.1600-0609.2002.01654.x 10.1034/j.1600-0609.2002.01654.x 1:CAS:528:DC%2BD38XotVCktLk%3D 12225393
22. R Simon 1987 How large should a phase II trial of a new drug be? Cancer Treat Rep 71 1079 1085 1:STN:280:DyaL1c%2Flt1OjsQ%3D%3D 3315196
23. T Takagi M Oguro 1987 (2″-R)-4′-o- tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies Cancer Chemother Pharmacol 20 151 154 10.1007/BF00253970 10.1007/BF00253970 1:STN:280:DyaL1c%2FislCrtg%3D%3D 3478154
24. H Tsurumi T Yamada M Sawada S Kasahara N Kanemura Y Kojima K Fukuno T Hara M Saio T Takahashi M Oyama K Ozawa T Takami H Moriwaki 2004 Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study J Cancer Res Clin Oncol 130 107 113 10.1007/s00432-003-0508-9 10.1007/s00432-003-0508-9 1:CAS:528:DC%2BD2cXhtlehsL8%3D 14648210 (Pubitemid 38316674)
25. H Tsurumi T Hara N Goto N Kanemura S Kasahara M Sawada I Yasuda T Yamada M Shimizu T Takami H Moriwaki 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 107 114 10.1002/hon.815 10.1002/hon.815 1:CAS:528:DC%2BD2sXht1SrsbzP 17457949 (Pubitemid 47507877)
26. H Umezawa Y Takahashi M Kinoshita H Naganawa T Masuda M Ishizuka K Tatsuta T Takeuchi 1979 Tetrahydropyranyl derivatives of daunomycin and adriamycin J Antibiot (Tokyo) 32 1082 1084 1:CAS:528:DyaL3cXjsVSltQ%3D%3D